Therapeutic potential of endogenous hydrogen sulfide inhibition in breast cancer (Review)

MING LI¹, YA LIU¹, YUYING DENG¹, LIMIN PAN¹, HAN FU¹, XUE HAN¹, YUXI LI¹, HAIMEI SHI² and TIANXIAO WANG¹

¹School of Pharmacy, Henan University, Kaifeng, Henan 475004; ²Department of Anesthesiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 450052, P.R. China

Received December 14, 2020; Accepted March 8, 2021

DOI: 10.3892/or.2021.8019

Abstract. Hydrogen sulfide (H₂S), the third gas signal molecule, is associated with the modulation of various physiological and pathological processes. Recent studies have revealed that endogenous H₂S may promote proliferation, induce angiogenesis and inhibit apoptosis, thereby stimulating oncogenesis. Conversely, decreased endogenous H₂S release suppresses growth of various tumors including breast cancer. This observation suggests an alternative tumor therapy strategy by inhibiting H₂S-producing enzymes to reduce the release of endogenous H₂S. Breast cancer is the most common type of cancer in women. Due to the lack of approved targeted therapy, its recurrence and metastasis still affect its clinical treatment. In recent years, significant progress has been made in the control of breast cancer by using inhibitors on H₂S-producing enzymes. This review summarized the roles of endogenous H₂S-producing enzymes in breast cancer and the effects of the enzyme inhibitors on anticancer and anti-metastasis, with the aim of providing new insights for the treatment of breast cancer.

Contents

1. Introduction
2. Endogenous H₂S-producing enzymes
3. Role of the CBS/H₂S system in breast cancer
4. Role of CSE/H₂S axis in breast cancer
5. Effect of CBS inhibition in breast cancer
6. Effect of CSE inhibition in breast cancer
7. Conclusions and perspectives

1. Introduction

Hydrogen sulfide (H₂S) is an endogenous gasotransmitter produced by mammalian tissues and cells that express three enzymes, namely cystathionine γ-lyase (CSE), cystathionine β-synthase (CBS), and 3-mercaptopyruvate sulfurtransferase (3-MST) (1-3). H₂S, together with nitric oxide (NO) and carbon monoxide (CO), constitute a family of endogenous gases that participate in modulating multiple physiological and pathological processes (4-7). In particular, they exhibit pleiotropic and often dose-dependent effects on a variety of diseases, including immunoinflammatory, autoimmune diseases and cancers (8-12). Therefore, their therapeutic potential has recently received increasing attention and some compounds capable of inhibiting or stimulating the synthesis or promoting the release of these gases have been developed in preclinical and clinical setting. Examples include NO-releasing drugs such as NO-aspirin, JS-K and NO-derivatives of antiretroviral protease inhibitors. They are mainly utilized for research on the prevention and treatment of cancer (13-17). In terms of immunoinflammatory and autoimmune diseases (18-20), CO-releasing drugs have exhibited certain efficacy. For numerous years, H₂S has been considered a health concern, and it is physiologically beneficial at low concentrations while toxic at high doses (21). However, previous evidence acquired at both preclinical and clinical settings demonstrated that H₂S donor compounds such as H₂S-naproxene have potential anti-inflammatory effects, highlighting an anti-inflammatory potential of H₂S (22). In cancer cells, H₂S donors have exhibited a beneficial chemotherapeutic action in a manner that depends on H₂S donor doses and cancer status. In other words, the biological response of H₂S donors follows a biphasic dose effect, which is characterized by cytoprotective or cytotoxic effects in cancer, that is, low levels of exogenous H₂S can induce oncogenesis, while high concentrations of exogenous H₂S production can prevent the development of tumors (23-26). Considering that the presence of endogenous H₂S can also induce tumorigenesis (22), inhibitors have been
developed to prevent the production of endogenous H$_2$S and proven effective in anti-cancer treatment (27-29). This review summarized the biological effects of endogenous H$_2$S related to breast cancer cell biology, to review the experimental evidence on the role of endogenous cancer cell-derived H$_2$S in breast cancer biology, and to outline the therapeutic potential of cystathionine-β-synthase (CSE) or cystathionine-γ-lyase (CBS) inhibition for breast cancer therapy.

2. Endogenous H$_2$S-producing enzymes

In mammalian tissues and cells, three enzymes, two cytosolic enzymes CBS and CSE, and one mitochondrial enzyme 3-mercaptopyruvate sulfurtransferase (3MST) control the synthesis of H$_2$S (30) (Fig. 1). In addition, they participate in the progression of various cancers (31).

Cystathionine-β-synthase (CBS). CBS is the first enzyme in the trans-sulfuration pathway and produces H$_2$S mainly through catalyzing homocysteine and cysteine. In the presence of homocysteine, CBS catalyzes its condensation with serine to form cystathionine, which is then cleaved by cystathionine γ-lyase (CTH) to form cysteine (32,33); CBS continues to catalyze it to generate H$_2$S through β-replacement reaction accompanied by the generation of serine.

CBS protein consists of four subunits and each subunit contains three domains (34). The N-terminal domain binds to a cofactor heme, which is responsible for successful protein folding. The C-terminal CBS1 and CBS2 domains bind to S-adenosylmethionine (SAM), which are responsible for CBS subunit tetramerization (33). The activity of CBS is mainly regulated by the modification of the heme group at the N-terminus and the binding of SAM at the C-terminus on the protein. The modification of the Fe (II) form of the heme caused by NO inhibits CBS activity and H$_2$S generation (35) while SAM binding activates CBS thereby increasing H$_2$S production (36).

CBS is predominantly expressed in the brain, liver, kidney, and pancreas and consequently exerts multiple biological and pathological functions in the cardiovascular, immune and central nervous systems by regulating the homocysteine and H$_2$S metabolism (37). Notably, compared to adjacent normal tissue or non-transformed cells, CBS expression was increased in tumor tissues and cell lines including breast cancer, suggesting its participation in the process of cancer (38-41), therefore, the overexpression of CBS may be an important factor in the development of tumors.

Cystathionine-γ-lyase (CSE). Similar to CBS, CSE also utilizes homocysteine and cysteine as substrates to generate H$_2$S along with the production of by-products such as α-ketobutyrate, pyruvate and ammonia (37). The relative concentrations of homocysteine and cysteine determine the primary substrate for CSE to produce H$_2$S in mammalian cells. At physiological concentrations of homocysteine and cysteine, CSE contributes approximately 70% of the total H$_2$S content from cysteine, whereas approximately 90% of H$_2$S is derived from homocysteine when its level increases to a level comparable to hyperhomocysteinemia (42).

Structurally, CSE protein is a tetramer composed of two dimers and each monomer binds one pyridoxal phosphate (PLP) (43). Analysis of genetic variations of the CSE-encoding genes has revealed a large number of polymorphisms. CSE activity is influenced by the intracellular Ca$^{2+}$ concentration: A low level induces H$_2$S production whereas a high level suppresses CSE activity (44). However, the exact mechanism of Ca$^{2+}$-mediated regulation of CSE activity remains to be further studied.

CSE is broadly expressed in tissues such as the liver, kidney, uterus, pancreatic islets and cardiovascular system as well as the respiratory system (45-47). However, overexpression of CSE genes in cells leads to increased production of H$_2$S, and consequently induces vasorelaxation, and stimulates endothelial cell-related angiogenic properties (48,49). In terms of mechanism, CSE gene expression is enhanced by estradiol (E2) through ER-Sp1 interaction with the binding sites in CSE gene promoter and consequently increases endothelial H$_2$S release (50,51). Moreover, recent studies have also revealed that E2 nongenomically induced vascular endothelial H$_2$S release by promoting CSE phosphorylation (52). Notably, CSE expression in breast cancer tissues and cells was increased when compared with adjacent normal tissue and cells, and this promoted the process of breast cancer (53,54).

3MST. 3MST also utilizes cysteine as substrate to generate H$_2$S. Here, cysteine aminotransferase (CAT) firstly converts cysteine into 3-mercaptopyruvate (3MP). Under the action of MST3, MP then transfers a sulfur atom onto 3MST, eventually in the presence of reductant such as thioredoxin, resulting in the formation of persulfide and the release of H$_2$S (55).

3MST activity is intrinsically regulated by its redox state and three redox-sensitive cysteines (Cys154, Cys247 and Cys263) which locate at the catalytic site of the enzyme (56). Studies have shown that oxidative stress could significantly suppress the activity of 3MST (57).

3MST is also expressed in numerous tissues such as myocardial, liver, as well as brain, and consequently exhibits some biological and biochemical features such as its partial mitochondrial localization and its ability to produce polysulfides (58-60). Recent data revealed its potential role in cancer biology since it is upregulated in colon adenocarcinoma, lung adenocarcinoma and various forms of oral carcinomas when compared to the surrounding normal tissues. Emerging data using 3MST silencing approaches or pharmacological inhibitors of 3MST suggest that the 3MST/H$_2$S system plays a role in maintaining cancer cell proliferation and regulating bioenergetic functions (61).

3. Role of the CBS/H$_2$S system in breast cancer

CBS expression in tumor tissues and cell lines has been reported to be increased in colon, ovarian, and prostate (38-41), compared to adjacent normal tissue or non-transformed cells. Similar findings have also been observed in breast cancer, where CBS-derived H$_2$S was revealed to protect breast cancer cells from the attack of microphages. Furthermore, silencing of CBS in the cells significantly attenuated tumor growth in a xenograft model (62) while overexpressing CBS in human breast cancer resulted in cystathionine accumulation, which protected human breast cancer cells against excess reactive oxygen species (ROS) and chemotherapeutic drug-induced
apoptosis (63). In addition, the existence of a large number of mutations and polymorphisms modifies the functions of the CBS gene (64). For instance, 844ins68 polymorphism in the CBS gene can not only alter the stability of a domain or residue in the hydrophobic core, leading to protein degradation, but also cause the increase of plasma homocysteine and methionine, leading to genomic DNA hypomethylation (65), ultimately impacting breast cancer oncogenesis (66-68), which further consolidated the pro-cancer effect of CBS in human breast cancer.

Collectively, it has been revealed that CBS overexpression significantly contributes to the pathogenesis of breast cancer cells, and CBS silencing can exert significant antitumor effects in vitro and in vivo. Based on these findings, it has been proposed that the pharmacological inhibitory effect of CBS can confer CBS an antitumor therapeutic potential. The role of the CBS/H₂S axis in breast cancer is presented in Fig. 2.

4. Role of CSE/H₂S axis in breast cancer

The role and functional mechanism of CSE in breast cancer reveal a variety of characteristics. CSE expression has been revealed to be upregulated in both breast cancer tissues and breast cancer cell lines, resulting in proliferation and migration of breast cancer cells (53,54). A previous study has revealed that the role of CSE in breast cancer leading to breast cancer development is associated with the STAT3 signaling pathway, specifically, STAT3 binds to and activates the CSE promoter to stimulate CSE expression (53). Moreover, CSE could reversely regulate STAT3 expression and consequently enhance the effect of STAT3 on CSE. CSE also may promote the metastasis of breast cancer via the SIRT1/acetyl STAT3 pathway and consequently enhance the effect of STAT3 on CSE. CSE also may promote the metastasis of breast cancer via the VEGF signaling pathway. CBS, cystathionine β-synthase; H₂S, hydrogen sulfide; CSE, cystathionine γ-lyase; 3MST, 3-mercaptopyruvate sulfurtransferase; CAT, cysteine aminotransferase; 3MP, 3-mercaptopyruvate.

Figure 2. Roles and mechanisms of CBS/H₂S and CSE/H₂S system in breast cancer. The overexpression of CBS and CBS gene polymorphism in human breast cancer results in the accumulation of cystathionine, which protects human breast cancer cells against excess ROS and chemotherapeutic drug-induced apoptosis. STAT3 may promote CSE expression via activation of the CSE promoter and CSE could reversely regulate STAT3 expression via the SIRT1/acetyl STAT3 pathway and consequently enhance the effect of STAT3 on CSE. CSE also may promote the metastasis of breast cancer via the VEGF signaling pathway. CBS, cystathionine β-synthase; H₂S, hydrogen sulfide; CSE, cystathionine γ-lyase; ROS, reactive oxygen species; SIRT1, sirtuin 1; STAT3, signal transducer and activator of transcription 3; VEGF, vascular endothelial growth factor; PI3K, phosphatidylinositol 3-kinase; Akt, protein kinase B; FAK, focal adhesion kinase; Ras, rat sarcoma; Raf, rapidly accelerated fibrosarcoma; ERK, extracellular signal-regulated protein kinase.

5. Effect of CBS inhibition in breast cancer

Aminoxyacetic acid (AOAA) and its methylated derivative. Consistent with the roles of CBS in breast cancer biology aforementioned, CBS inhibitors have exhibited great potential in breast cancer therapy. An example is AOAA (Fig. 3), a classical CBS inhibitor. Its inhibitory effect on breast cancer has been observed in breast cancer cells and BALB/c nude mice bearing MDA-MB-231 human breast cancer subcutaneous xenografts (71). Its mechanism of action has been revealed to be related to the suppression of tumor cell bioenergetics, especially due to AOAA-mediated inhibition of tumor cell aspartate aminotransferase activity (71). In a previous study, a methylated derivative of AOAA, YD0171 (Fig. 3), was also revealed to be active. It exhibited higher potency in inhibiting...
the growth of cancer cells \textit{in vitro} and \textit{in vivo} (72). However, whether AOAA has sufficient therapeutic effect for breast cancer requires further investigation. Not only is its effect on non-cancerous cells not clear, but it also irreversibly binds to the cofactor PLP. Therefore, in addition to inhibiting CBS, it has been revealed to also inhibit other PLP-dependent enzymes such as CTH, 3-MST, and glutamate oxaloacetate transaminase 1 (GOT1) (73,74). All of these pose high challenges to the development of selective CBS inhibitors as therapeutic drugs.

\textit{Selective CBS inhibitors.} To identify novel selective CBS inhibitors, several groups pursued screening tests and determined that some compounds can inhibit CBS (75-78). Using a tandem-microwell assay, Zhou \textit{et al} in 2013 (75) revealed a hit, 3-benzyl-1,6-dimethylpyrimido(5,4-e)(1,2,4)triazine-5,7(1H,6H)-dione, naming it CH004 (Fig. 3). which was the focus of a follow-up study published in 2018 (76). The IC$_{50}$ of CH004 for CBS was <1 µM and its selectivity for CBS was ~30 times higher than that for CSE, thus it may be the most effective CBS inhibitor to date (76). Moreover, CH004 was revealed to possess anti-breast cancer effects in CBS highly-expressed breast cancer cells, with IC$_{50}$ values in the range of 10-20 µM (77). Using a yeast-based screening model, Marechal \textit{et al} identified disulfiram (Fig. 3) as a putative inhibitor of cellular CBS activity (78). Despite its pattern of action being unclear, disulfiram has been developed as a potential anticancer drug in multiple tumor types, including breast cancer (79-83). Some therapeutic protocols that include disulfiram as part of combination therapy have also been used in clinical trials (84-86). Quinaldine blue (Fig. 4), an antitumor drug approved by the FDA, may also be a CBS selective inhibitor since it has been revealed to inhibit tumor growth by selectively suppressing the activity of CBS and has a preference to inhibit CBS over CSE (87). Applying an H$_2$S probe-based assay onto a chemical library containing 1,900 compounds (88), Thorson \textit{et al} revealed that 1,4-naphthoquinone and tangeritin (Fig. 4) could selectively suppress CBS activity without affecting CSE activity. They further demonstrated that both compounds possessed potential anticancer activities. Compound benserazide (Fig. 4) exhibited CBS-inhibitory activity in both a tandem-microwell screening assay and an H$_2$S probe-based screening assay (75,88). Although it is more effective than AOAA in weakening cellular bioenergetics and proliferation rate in colorectal cancer cell lines (89), its role in breast cancer is unclear. Some other selective inhibitors of CBS that have begun to attract attention in cancer biology, include 6S, NSC67078 and Sikokianin C (Fig. 5) (90,91), however, their effects on cancer cell proliferation require further elucidation.
6. Effect of CSE inhibition in breast cancer

Propargylglycine (PAG), β-cyanoalanine (BCA) and L-aminoethoxyvinylglycine (AVG). PAG, BCA (Fig. 4) and AVG (Fig. 5) are three classical CSE inhibitors. Despite BCA being more potent than PAG, both BCA and PAG could significantly suppress the proliferation of human gastric cancer AGS cells in a concentration-dependent manner (92). However, the role of PAG and BCA in breast cancer has not been reported. Similar to PAG, AVG has been revealed to selectively inhibit...
CSE only at a markedly lower concentration (74). Its role in breast cancer remains unknown.

**Other selective CSE inhibitors.** To identify novel selective CSE inhibitors, several groups screened and confirmed that certain compounds can inhibit CSE. Using a tandem-well-based high-throughput assay, NSC4056 (Fig. 5), also known as aurintricarboxylic acid, was identified as the most potent inhibitor with an IC_{50} of 0.6 µM for CSE. It was revealed to selectively bind to Arg and Tyr residues in the active site of CSE, and preferably inhibit the CSE activity in cells but did not inhibit CBS (93). Another compound 2-arylidene hydrazinecarbodithioates (Fig. 5) was revealed to be more active than the benchmark inhibitors, and notably, it had higher selectivity for CSE compared to CBS (94). S-3-carboxpropyl-L-cysteine (CPC) (Fig. 5), a new CSE inhibitor, inhibited the \( \gamma \)-elimination reaction of cystathionine and \( \text{H}_2\text{S} \) synthesis from cysteine by human CSE (95). However, the inhibition did not depend on the order of substrate/inhibitor addition. Currently, there remains a lack of studies on NSC4056 and 2-arylidene hydrazinecarbodithioates as well as CPC in the context of cancer therapy.

In our previous study (96), a virtual screening method was used to search for CSE inhibitors based on the crystal structure of the CSE protein. MOE Dock (Chemical Computing Group ULC) was further used to simulate the hits and predict their docking affinity with the homology model. Among the final top 12 candidates selected (Fig. 6), I157172 (Fig. 3) had the lowest binding score of -7.9215 and the highest binding affinity. I157172 inhibited the growth, proliferation and migration of breast cancer cells via upregulation of SIRT1, which consequentially mediated deacetylation of STAT3 and inactivation of the STAT3 pathway (93). In addition, I157172 inhibited the metastasis of MDA-MB-231 cells via downregulation of the expression of VEGF and numerous of its downstream key proteins, including PI3K, Akt, pAkt, FAK, Paxillin, Raf and pERK1/2, and this may be one of the underlying molecular mechanisms by which CSE inhibition promotes breast cancer metastasis (96). I194496 (Fig. 3) was the second most effective CSE inhibitor with a binding score of -7.9042. Our recent study revealed that I194496 could inhibit the growth of human TNBC cells via dual targeting of the PI3K/Akt and Ras/Raf/ERK pathways and suppress the metastasis of human TNBC cells via downregulation of the Anxa2/STAT3 and VEGF/FAK/Paxillin signaling pathways (unpublished data).

### 7. Conclusions and perspectives

Currently, the treatment of breast cancer is mainly postoperative adjuvant chemotherapy or radiotherapy. Patients not only have to endure the side effects of long-term chemotherapy or radiotherapy, but also have to bear the risk of metastasis and recurrence. Therefore, targeted therapy is particularly
important for breast cancer. Recently, endogenous gas transmitter \( \text{H}_2\text{S} \) has been revealed to be responsible for breast cancer development. Accordingly, study of the mammalian enzymes responsible for \( \text{H}_2\text{S} \) production has become an attractive strategy in breast cancer therapy. Although the overexpression of CBS and CSE significantly promoted the pathogenesis of breast cancers, the exact mechanism of CBS and CSE remains poorly understood, as well as the role of 3-MST expression in breast cancer. In view of the evidence that inhibition of CBS can prevent proliferation of breast cancer and induce apoptosis of breast cancer, inhibiting \( \text{H}_2\text{S} \) biosynthesis by targeted \( \text{H}_2\text{S} \)-producing enzymes may confer antitumor effects.

Regarding the pharmacological inhibitors CBS and CSE, this review provided a historical background and the latest pharmacological information regarding small molecules called ‘CBS inhibitors’ and ‘CSE inhibitors’. It is emphasized that currently known compounds can only be used with great caution to study the biological roles of CBS and CSE. Numerous of the compounds are not ideal or remain to be assessed in terms of anti-breast cancer properties. To advance CBS and CSE inhibitors into clinical trials, not only is a comprehensive study required to improve the pharmacological properties of these molecules, but also the mechanism regarding the sensitivity of CBS and CSE inhibitors to breast cancer requires further exploration. It is anticipated that this review on the inhibitory effects of endogenous \( \text{H}_2\text{S} \) on breast cancer can stimulate further development in this field.

Acknowledgements

No applicable.

Funding

The present study was supported by grants from the National Natural Science Foundation of China (grant no. 82072726), as well as the Natural Science Foundation of Henan Province in China (grant no. 202300410079).

Availability of data and materials

No applicable.

Authors' contributions

ML, HS and TW conceived the subject of the review. TW designed the review. ML, YL, YD and LP wrote the manuscript, performed the literature research as well as interpreted the relevant literature. HF, XH and YL prepared the figures and analyzed the review critically for important intellectual content. ML and YL edited and revised the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Szabo C: Gaseotransmitters: New frontiers for translational science. Sci Transl Med 2: 59ps54, 2010.
2. Kabil O and Banerjee R: Enzymology of \( \text{H}_2\text{S} \) biosynthesis, decay and signaling. Antioxid Redox Signal 20: 770-782, 2014.
3. Kimura H: Hydrogen sulfide: Its production, release and functions. Amino Acids 41: 113-121, 2011.
4. Mani S, Untereiner A, Wu L and Wang R: Hydrogen sulfide and the pathogenesis of atherosclerosis. Antioxid Redox Signal 20: 805-817, 2014.
5. Wu D, Wang J, Li H, Xue M, Ji A and Li Y: Role of hydrogen sulfide in ischemia-reperfusion injury. Oxid Med Cell Longev 2015: 186908, 2015.
6. Szabó C: Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 6: 917-935, 2007.
7. Wang R: Physiological implications of hydrogen sulfide: A whiff exploration that blossomed. Physiol Rev 92: 791-896, 2012.
8. Fagone P, Mazzon E, Bramanti P, Bendtzen K and Nicoletti F: Gaseotransmitters and the immune system: Mode of action and novel therapeutic targets. Eur J Pharmacol 834: 92-102, 2018.
9. Mintz J, Vedenko A, Rosete O, Shah K, Goldstein G, Hare JM, Ramasamy R and Arora H: Current advances of nitric oxide in cancer and anticancer therapeutics. Vaccines (Basel) 9: 94, 2021.
10. Motterlini R and Oterbein LE: The pharmacological potential of carbon monoxide. Nat Rev Drug Discov 9: 728-743, 2010.
11. Lazarević M, Battaglia G, Jevtić B, Dedović N, Bruno V, Cavalli E, Miljković D, Nicoletti F, Momčilović M and Fagone P: Upregulation of tolerogenic pathways by the hydrogen sulfide donor GYY4137 and impaired expression of \( \text{H}_2\text{S} \)-producing enzymes in multiple sclerosis. Antioxidants (Basel) 9: 608, 2020.
12. Lazarević M, Mazzon E, Momčilović M, Basile MS, Colletti G, Petralia MC, Bramanti P, Nicoletti F and Miljković M: The \( \text{H}_2\text{S} \) donor GYY4137 stimulates reactive oxygen species generation in BV2 cells while suppressing the secretion of TNF and nitric oxide. Molecules 23: 2966, 2018.
13. Gao L and Williams JL: Nitric oxide-donating aspirin induces G2/M phase cell cycle arrest in human cancer cells by regulating phase transition proteins. Int J Oncol 41: 325-330, 2012.
14. Furuhashi S, Sugita H, Takamori H, Horino K, Nakahara O, Okahe H, Miyake K, Tanaka H, Beppu T and Baba H: NO donor and MEK inhibitor synergistically inhibit proliferation and invasion of cancer cells. Int J Oncol 40: 807-815, 2012.
15. Muratovic V, Saavedra JE, Nieves-Alicea R, Simeone AM, Maksimovic-Ivanic D, Fagone P, McCubrey J, Bendtzen K and Nicoletti F: HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives? Int J Cancer 140: 1713-1726, 2017.
16. Maksimovic-Ivanic D, Fagone P, McCubrey J, Bendtzen K, Mijatovic S and Nicoletti F: HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives? Int J Cancer 140: 1713-1726, 2017.
17. Ruthweiler F, Michaelis M, Brauer P, Otte J, Weber K, Felbue B, Doerr HW, Wiese M, Kreuter J, Al-Abed Y, et al: Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia 12: 1023-1030, 2010.
18. Nikolic I, Saksida T, Mangano K, Vujicic M, Stojanovic I, Nicoletti F and Stosic-Grudic S: Pharmacological application of carbon monoxide ameliorates islet‑directed autoimmunity in mice via anti-inflammatory and anti-apoptotic effects. Diabetologia 57; 980-990, 2014.
19. Fagone P, Mangano K, Coco M, Perciai Valletta V, Garotta G, Romao CC and Nicoletti F: Therapeutic potential of carbon monoxide in multiple sclerosis. Clin Exp Immunol 167: 179-187, 2012.
20. Fagone P, Mangano K, Quattrocchi C, Muterlini R, Di Marco R, Magro G, Penacho N, Romao CC and Nicoletti F: Prevention of clinical and histological signs of proteolipid protein (PLP)-induced experimental allergic encephalomyelitis (EAE) in mice by the water-soluble carbon monoxide-releasing molecule (CORM)-A1. Clin Exp Immunol 163: 368-374, 2011.
21. Molis K, Wolanska K and Vozdek R: Hydrogen sulfide in cell signaling, signal transduction, cellular bioenergetics and physiology in \textit{C. elegans}. Gen Physiol Biophys 32: 1-22, 2013.
22. Wallace JL, Ferraz JG and Muscara MN: Hydrogen sulfide: An endogenous mediator of resolution of inflammation and injury. Antioxid Redox Signal 17: 58-67, 2012.

23. D'U, Si, Wang M, Li Y, Ji A and Li Y: Hydrogen sulfide in cancer: Friend or foe? Nitric Oxide 50: 38-45, 2015.

24. Ngowi EE, Afzal A, Sarrafz M, Khattak S, Zaman SU, Khan NH, Li T, Jiang QY, Zhang X, Duan SF, et al.: Role of hydrogen sulfide donors in cancer development and progression. Int J Biol Sci 17: 131-139, 2021.

25. Lee ZW, Zhou J, Chen CS, Zhao Y, Tan CH, Li L, Moore PK and Deng LW: The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. PLoS One 6: e21077, 2011.

26. Lu S, Gao Y, Huang X and Wang X: GYY4137, a hydrogen sulfide donor with the potential to inhibit tumorigenesis and extracellular matrix protein production by human colon cancer cells: in vitro and in vivo. Exp Pharmacol 230: 233-241, 2015.

27. Sonke E, Verrydt M, Postenka CO, Pardhan S, Willie CJ, Mazzola CR, Hamers MD, Pluth MD, Lobb J, Power NE, et al.: Inhibition of endogenous hydrogen sulfide production in clear-cell renal carcinoma cell lines and xenografts restricts their growth, survival and angiogenic potential. Nitric Oxide 49: 26-39, 2015.

28. Oláh G, Módis K, Tóró G, Hellmich MR, Szczesny B and Szabo C: Role of endogenous and exogenous nitric oxide, carbon monoxide and hydrogen sulfide in lung cancer cell proliferation. Biochem Pharmacol 149: 186-204, 2018.

29. Hellmich MR and Szabo C: Hydrogen sulfide and cancer. Handb Exp Pharmacol 230: 233-241, 2015.

30. Dilek N, Papapetropoulos A, Toliver-Kinsky T and Szabo C: Hydrogen sulfide: An endogenous regulator of the immune system. Pharmacol Res 161: 105119, 2020.

31. Szabo C: Hydrogen sulfide, an endogenous stimulator of mitochondrial function in cancer cells. Cells 10: 220, 2021.

32. Jhee KH and Kruger WD: The role of cystathionine beta-synthase in homocysteine metabolism. Antioxid Redox Signal 7: 813-822, 2005.

33. Zhu H, Blake S, Chan KT, Pearson RB and Kang J: Cystathionine β-synthase in physiology and cancer. Biomed Res Int 2018: 2305125, 2018.

34. Erero-Orbea J, Majtan T, Oyenarte I, Kraus JP and Martínez-Cruz LA: Structural basis of regulation and oligomerization of human cystathionine β-synthase, the central enzyme of transsulfuration. Proc Natl Acad Sci USA 110: E3790-E3799, 2013.

35. Lambertini E, Penolazzi L, Angelozzi M, Grassi F, Gamberi L, Lisignoli G, De Bonis P, Cavallo M and Piva R: The expression of cystathionine gamma-lactase is regulated by estrogen receptor alpha in human osteoblasts. Oncotarget 8: 101686-101696, 2017.

36. Xu X, Yan Q, Liu X, Li P, Li X, Chen Y, Simoncini T, Liu J, Zhu D and Fu X: 17β-Estradiol attenuates atherosclerosis development: The possible role of hydrogen sulfide. Int J Cardiol 167: 1061-1063, 2013.

37. Li M, Xu C, Shi J, Ding J, Wan X, Chen D, Gao J, Li C, Zhang J, Lin Y, et al.: Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopurine/sulfurtransferase/hydrogen sulfide pathway. Biochem Biophys Res Commun 433: 401-407, 2013.

38. Jreddi S, Gholami H, Gheibi S, Kashfi K and Ghasemi A: Altered gene expression of hydrogen sulfide-producing enzymes in the liver and muscles tissues of hyperthyroid rats. J Cell Physiol 234: 17937-17945, 2019.

39. Huang CW and Moore PK: H2S synthesizing enzymes: Biochemistry and molecular aspects. Handb Exp Pharmacol 230: 3-25, 2015.

40. Li M, Xu C, Shi J, Ding J, Wan X, Chen D, Gao J, Li C, Zhang J, Lin Y, et al.: Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopurine/sulfurtransferase/hydrogen sulfide pathway. Biochem Biophys Res Commun 433: 401-407, 2013.

41. Augsburger F and Szabo C: Potential role of the 3-mercaptopurine/sulfurtransferase/hydrogen sulfide (H2S) pathway in cancer cells. Pharmacol Res 154: 104083, 2020.

42. Sen S, Kawahara B, Gupta D, Tsai R, Khachatryan M, Rajkanjoo S, Bowdhuari S, Bashir MA, Faull K, Farías-Eisner R and Chaudhuri G: Role of cystathionine β-synthase in human breast cancer. Free Radic Biol Med 86: 228-238, 2015.
Asimakopoulou A, Panopoulos P, Chasapis CT, Coletta C, Gallegos-Arreola MP, Figuera-Villanueva LE, Ramos-Silva A, Stevens VL, McCullough ML, Pavluck AL, Talbot JT, Weiner AS, Boyarskikh UA, Voronina EN, Selezneva IA, Sen S, Kawahara B, Mahata SK, Tsai R, Yoon A, Hwang L, Kraus JP, Oliveriusová J, Sokolová J, Kraus E, Vlcek C, Marechal D, Brault V, Leon A, Martin D, Lopes Pereira P, Hellmich MR, Coletta C, Chao C and Szabo C: The therapeutic potential of cystathionine β-synthase inhibitors using a hydrogen sulfide signaling pathway. Identification of additional anti-persister activity against Borrelia burgdorferi from an FDA drug library. Anticancer Agents Med Chem 16: 397-410, 2015.

Thornson MK, Majtan T, Kraus JP and Barrios AM: Identification of cystathionine β-synthase inhibitors as a well-characterized pharmacological compounds for cystathionine γ-lyase-dependent hydrogen sulfide synthesis. J Biol Chem 294: 1677-1683, 2019.

Wang L, Cai H, Hu Y, Liu F, Huang S, Zhou Y, Yu J, Liu F, A pharmacological probe identifies cystathionine β-synthase as a new negative regulator for ferroptosis. Cell Death Dis 9: 1005, 2018.

Zhu K, Augebarger F, Majtan T and Szabo C: Cystathionine-β-synthase: Molecular regulation and pharmacological inhibition. Biochim Biophys Acta 1897, 2020.

Marechal D, Brault V, Leon A, Martin D, Lopes Pereira P, Loaec N, Birling MC, Fricourt G, Blondel M and Herault Y: Identification of potential new cryoprotective agents. Cryobiology 58: 95-102, 2016.